Sentences with phrase «epipen in»

Tell your flatmates about your allergy and the seriousness of it, especially if you need an EpiPen in the event of a bad reaction to food.

It's also a bad idea to keep your EpiPen in the car, where it can be exposed to temperature extremes that make it less effective.

At least two companies are seeking approval to sell a rival brand or generic version of EpiPen in the United States, but none are likely to be available until later next year.

Our fast - acting (and highly allergic) nurse rushed out of the room and made it to her EpiPen in time.

For example: Cigna's decision this week to drop coverage of the EpiPen in favor of a cheaper competitor and pharmacy benefits manager Express Scripts» original controversial decision to snub Gilead's hep C cure Sovaldi in favor of a competitor from AbbVie.

There are two main parts to the investigation: 1) whether or not Mylan engaged in «product hopping,» or making small tweaks to the EpiPen in order to preserve IP protection; and 2) whether or not the pharma giant entered into certain agreements that stalled the entry of cheaper generics into the market.

The company recently said it is going to pay $ 465 million to the Department of Justice and other government agencies over the way it classified the EpiPen in the Medicaid Drug Rebate Program.

As a working parent fortunate enough to have solid health insurance, I can curse my $ 60 copay (the highest tier in my «gold» insurance plan, and twice what it was when I started buying EpiPens in 2009) and plunk down a credit card.

Not exact matches

«Your own data show that you received hundreds of complaints that your EpiPen products failed to operate during life - threatening emergencies, including some situations in which patients subsequently died,» the FDA wrote.

We are very confident in the safety and efficacy of EpiPen products being produced at the site.»

Rajiv Malik, president and executive director at EpiPen maker Mylan (essentially the company's number two exec), has been named in a wide - ranging civil suit alleging drug price collusion by numerous prominent generic drug makers.

Mylan drew major flak last year after news broke that it had steadily increased the list price for an EpiPen two - pack from about $ 100 to more than $ 600 in less than a decade.

It's not just the insulin market that is doing this: The same thing happened with the EpiPen market when a competitor came in around 2013 and with multiple - sclerosis drugs.

As lawmakers and the public scrutinize dramatic price increases for other old drugs — most recently with the Mylan - owned EpiPen, which saw its cost go up by 500 % in the past nine years — the next flash point may be insulin, a drug both ubiquitous and complicated.

When customers, who were truly in need of a real solution, gained the EpiPen, they felt in control.

That is, in part, because the price of EpiPen is tied to Mylan's stock performance, and Mylan's stock performance is tied to executive compensation.

Congress seems to think that a trove of documents including anything prepared for the company's board having to do with the EpiPen, Mylan's tax rate, profits connected to the EpiPen, manufacturer contracts related to the EpiPen, anything related to EpiPen pricing in the Netherlands, and anything having to do with a generic EpiPen could help answer that question.

In Toronto, Amy Morrell keeps four EpiPens to protect her 5 - year - old son from a life - threatening peanut allergy.

Mylan bought EpiPen from Merck in 2007.

Mylan came under fire in August when it raised the price of the EpiPen, a lifesaving allergy drug, to $ 608 for a two - pack.

In conjunction with Mylan's SEC filing, a Mylan spokesperson stated that «the information provided to Congress has made clear that tax was part of the EpiPen Auto - Injector profitability analysis.»

In a CNBC interview in August, Bresch blamed this complexity and the middlemen that are able to profit from it for EpiPen's price hikeIn a CNBC interview in August, Bresch blamed this complexity and the middlemen that are able to profit from it for EpiPen's price hikein August, Bresch blamed this complexity and the middlemen that are able to profit from it for EpiPen's price hikes.

In response to a Reuters query, Pfizer said there was no shortage in the United States and that Mylan decides how EpiPens are allocated to different countrieIn response to a Reuters query, Pfizer said there was no shortage in the United States and that Mylan decides how EpiPens are allocated to different countriein the United States and that Mylan decides how EpiPens are allocated to different countries.

In a statement to CNBC, Mylan reiterated that it was following guidance from the federal government on the classification of EpiPens and it referred to a new government rule that intends to clarify ambiguities in Medicaid rebate laIn a statement to CNBC, Mylan reiterated that it was following guidance from the federal government on the classification of EpiPens and it referred to a new government rule that intends to clarify ambiguities in Medicaid rebate lain Medicaid rebate law.

Mylan, one of the 10 most heavily weighted stocks in the ETF, traded more than 1.5 percent higher despite recent political pressure over the stark price increases of its life - saving EpiPen device.

Health Canada has told consumers to use expired EpiPens and call 911 in an emergency if they have nothing else.

Mylan had not directly referenced the tax assumptions for its EpiPen profit estimates, neither in its September 15, 2016, letter to the Committee, nor in the documents that the company produced.»

In Canada, a single EpiPen can be bought for $ 100, while the UK National Health Service price for a single dose is closer to $ 38.

Mylan saw its stock dip almost a third of a percent during after - hours trading, following members of Congress saying it cheated taxpayers by underpaying Medicaid in rebates owed on sales of its lifesaving device EpiPen.

The EpiPen is a so - called «auto - injector» which delivers a jolt of epinephrine to the body in order to counteract anaphylaxis shock from allergies to peanuts, shell food, and other substances.

Its brand has become synonymous with Kleenex and other household products when it comes to fighting deadly allergies; in fact, the EpiPen enjoys a near - monopoly on the market with annual sales of more than $ 1.3 billion and nearly 90 % U.S. market share in the space.

And despite the fact that Mylan raised EpiPen prices roughly 30 % in 2015 while prescription volume also grew 7 %, the company's revenue on the drug actually fell slightly, as the other players took even bigger cuts, according to Raffat.

According to filings, Coury made roughly $ 98 million in 2016, the same year in which the company faced criticism for the price of the EpiPen and the stock fell by almost 30 %, according to company filings.

Mylan's CEO, Heather Bresch, later had to testify before Congress, class - action lawsuits have been filed against the company, and Mylan in May was accused of overcharging the US government by $ 1.27 billion for EpiPens.

And the risk of losing money also falls less on Mylan than it does on those at the end of the supply chain, with the pharmacy having to dispense EpiPens while accepting less in copay money upfront, then applying for a rebate and waiting to see what trickles back.

The generic pharmaceutical company came into the spotlight in August 2016 for raising the price of the EpiPen to $ 608.61 from $ 93.88 over the past decade.

Those middlemen are by no means starving: Mylan revealed on Thursday that it wasn't pocketing the full $ 608 EpiPen wholesale price in the first place, but only $ 274 per prescription, with the remaining $ 334 split between the other parties.

«I absolutely believe that if EpiPen had to be the catalyst to show this window of what families are facing in a high - deductible plan... then it would have been worth it,» the controversial big pharma chief told attendees at the Forbes Healthcare summit on Thursday.

One concern among analysts is how fallout over EpiPen pricing will affect Mylan's roughly $ 1 billion in annual sales of the device.

Bresch admitted that the EpiPen, which her company acquired in 2007, had become its first $ 1 billion device.

Clinton went on to reiterate her position that drug price hikes should be linked with better patient outcomes and demonstrated improvements in value, and demanded that Mylan «immediately reduce the price of EpiPens.»

In the first year Mylan owned EpiPen, its price increased nearly 5 %, to about $ 99 for a set of two EpiPens.

Bresch, who at the time was overseeing the Merck integration as president of Mylan (she became CEO in 2012), saw EpiPen as a hidden gem.

In a statement Monday, Mylan says it has tried to make EpiPen accessible and affordable to people who really need it, offering rebate cards that allowed 80 % of patients with commercial insurance to get the product for free last year.

Inside Mylan, executives including Bresch all refer to EpiPen as her «baby»: It's Mylan's first billion - dollar drug, reaching $ 1 billion in annual sales in 2014 and 2015 — making it what the pharmaceutical industry calls a «blockbuster.»

At the time, EpiPen was making less than $ 250 million in sales.

Her comments came shortly after the Senate Committee on Aging asked Mylan to provide information on the reasoning behind what it called the «drastic» price increase of EpiPen, and the American Medical Association «urge [d]» Mylan to «rein in these exorbitant costs.»

On an earnings call earlier this month, Bresch blamed EpiPen sticker shock in part on Obamacare.

Mylan has raised the price for the EpiPen, an auto - injector device that delivers epinephrine to counteract deadly allergic reactions which must be replaced on a yearly basis, more than 400 % over the last decade, putting families who have high deductible health insurance in a bind.

There's some bad news out there for Mylan's EpiPen — it's starting to hemorrhage market share to competitors in the wake of its price - gouging controversy.